Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 17 Oct 2022

Accurate and accessible testing for SARS-CoV-2 is a critical tool for the timely identification of infection to inform isolation recommendations, prevent transmission, and facilitate early initiation of therapy to reduce disease progression. More...

Rapid antigen tests for COVID-19 show great promise as a testing method that is easy to use, accessible, and cost-effective Rapid antigen tests (Ag-RDTs) have lower sensitivity than RT-PCR tests for detecting SARS-CoV-2, however, sensitivity can be improved through serial testing.

A large team of medical scientists at the University of Massachusetts Chan Medical School, Worcester, MA, USA) compared the performance of Ag-RDTs in detecting the Delta (B.1.617.2) and Omicron (B.1.1.529) variants of SARS-CoV-2. The team relied on data from the prospective cohort study Test Us At Home in which participants serially took both at-home antigen and send-in PCR COVID-19 tests over a period of 10 to 15 days. This analysis focuses on the 5,779 individuals who tested negative for SARS-CoV-2 at the start of the parent study and the 207 individuals of those who later tested positive for the virus by PCR.

On enrollment, participants were assigned to 1 of 3 Ag-RDTs with emergency use authorization: BD Veritor At-Home COVID-19 Test (Becton, Dickinson and Company, San Diego, CA, USA), Quidel QuickVue At-Home OTC COVID-19 Test (San Diego, CA, USA) and Abbott BinaxNOW COVID-19 Antigen Self-Test (Princeton, NJ, USA). Participants received the Ag-RDT and the Quest Diagnostics collection kit for COVID-19 by mail at the shipping address provided on enrollment.

The investigators reported that a total of 207 participants were positive on RT-PCR (58 Delta, 149 Omicron). Differences in sensitivity between variants were not statistically significant (same day: Delta, 15.5% [95% CI, 6.2% to 24.8%] versus Omicron, 22.1% [CI, 15.5% to 28.8%]; at 48 hours: Delta, 44.8% [CI, 32.0% to 57.6%] versus Omicron, 49.7% [CI, 41.6% to 57.6%]). Among 109 participants who had RT-PCR–positive results for 48 hours, rapid antigen sensitivity did not differ significantly between Delta- and Omicron-infected participants (48-hour sensitivity: Delta, 81.5% [CI, 66.8% to 96.1%] versus Omicron, 78.0% [CI, 69.1% to 87.0%]). Only 7.2% of the 69 participants with RT-PCR–positive results for shorter than 48 hours tested positive by Ag-RDT within one week; those with Delta infections remained consistently negative on Ag-RDTs.

The authors concluded that nasal swab Ag-RDT performance was similar between the Omicron and Delta variants. In both cases, detection of virus with Ag-RDTs was associated with relative viral load as measured by Ct value. The data suggest that serial testing continues to be important in improving the performance of Ag-RDTs. Future work to increase the understanding of persons with singleton RT-PCR positivity is needed to determine the public health significance of a false-negative Ag-RDT result in this subpopulation. The study was published on October 11, 2022 in the journal Annals of Internal Medicine.

Related Links:
University of Massachusetts Chan Medical School
Becton, Dickinson and Company
Quidel 
Abbott 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.